These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1536 related items for PubMed ID: 19154448

  • 41. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H.
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [Abstract] [Full Text] [Related]

  • 42. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F.
    Cancer; 2004 Dec 01; 101(11):2540-8. PubMed ID: 15481058
    [Abstract] [Full Text] [Related]

  • 43. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS.
    Urology; 2006 Apr 01; 67(4):737-41. PubMed ID: 16618564
    [Abstract] [Full Text] [Related]

  • 44. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR.
    J Urol; 2010 Jul 01; 184(1):81-6. PubMed ID: 20478593
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J, Gaya JM, Sabaté S, Palou J, Villavicencio H.
    Actas Urol Esp; 2010 Jan 01; 34(1):63-70. PubMed ID: 20223134
    [Abstract] [Full Text] [Related]

  • 48. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S, Wieland WF, Otto W, Filbeck T, Knuechel R, Burger M.
    BJU Int; 2008 Mar 01; 101(5):566-9. PubMed ID: 17986289
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL.
    Eur Urol; 2012 Apr 01; 61(4):705-11. PubMed ID: 22101114
    [Abstract] [Full Text] [Related]

  • 51. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T, Alter A, Wiechno P.
    Urol Int; 2008 Apr 01; 80(1):74-9. PubMed ID: 18204238
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May 01; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI, Tsolos C, Touloupidis S.
    Urology; 2007 Feb 01; 69(2):245-50. PubMed ID: 17320657
    [Abstract] [Full Text] [Related]

  • 56. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.
    BJU Int; 2004 Dec 01; 94(9):1258-62. PubMed ID: 15610101
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E, Iborra I, Ricos JV, Monros JL, Rubio J, Almenar S.
    J Urol; 2002 May 01; 167(5):2007-11. PubMed ID: 11956428
    [Abstract] [Full Text] [Related]

  • 60. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A, Cecchini L, Raventós CX, Trilla E, Planas J, Landolfi S, de Torres I, Morote J.
    BJU Int; 2010 Jan 01; 105(2):202-7. PubMed ID: 19558557
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 77.